- 36. The recombinant HSV of claim 31, wherein the rep polypeptide is an AAV rep40 protein.
- 37. The recombinant HSV of claim 31, further comprising an Intermediate Terminal Repeat (ITR) cassette, which comprises two AAV-derived ITR sequences flanking a non-ITR polynucleotide.
- 38. The recombinant HSV of claim 37, wherein the rep gene is not within the ITR cassette.
- 39. The recombinant HSV of claim 31, further comprising a cap gene comprising a promoter operatively linked to a polynucleotide sequence encoding an AAV cap polypeptide.
- 40. The recombinant HSV of claim 39, further comprising an ITR cassette, which comprises two AAV-derived ITR sequences flanking a non-ITR polynucleotide.
- 41. The recombinant HSV of claim 40, wherein the rep gene is not within the AAV ITR cassette.
- 42. The recombinant HSV of claim 31, which is deficient for at least one essential HSV.
- 43. The recombinant HSV of claim 42, wherein the essential HSV gene is an immediate early, early or late HSV gene.
  - 44. The recombinant HSV of claim 42, wherein the essential HSV gene is ICP27.
- 45. The recombinant HSV of claim 31, wherein the promoter is conditionally active.
- 46. The recombinant HSV of claim 31, wherein the promoter is a tissue specific promoter.
- 47. The recombinant HSV of claim 31, wherein the promoter is an HSV promoter.
- 48. The recombinant HSV of claim 31, which is replication incompetent in cells other than packaging cells.
  - 49. A viral stock comprising the recombinant HSV of claim 31.
- 50. A composition comprising the recombinant HSV of claim 31 and a physiologically-acceptable carrier.
  - 51. The composition of claim 50, which further comprises an ITR cassette.
- 52. The composition of claim 51, wherein the ITR cassette is within an HSV vector.
- 53. The composition of claim 50, further comprising a second HSV that comprises an ITR cassette.



- 54. A recombinant herpes simplex virus (HSV) comprising a rep gene, which comprises a promoter operatively linked to a polynucleotide encoding an adeno-associated virus (AAV) rep polypeptide, a cap gene, which comprises a promoter operatively linked to a polynucleotide sequence encoding an AAV cap polypeptide, and an Intermediate Terminal Cassette (ITR) cassette, which comprises two AAV-derived ITR sequences flanking a non-ITR polynucleotide, wherein the rep polypeptide or the promoter is conditionally active.
- 55. The recombinant HSV of claim 54, wherein the rep polypeptide is obtained from an AAV rep78, rep68, rep62, or rep40 protein.
- 56. The recombinant HSV of claim 54, wherein the rep polypeptide is an AAV rep78 protein.
- 57. The recombinant HSV of claim 54, wherein the rep polypeptide is an AAV rep68 protein.
- 58. The recombinant HSV of claim 54, wherein the rep polypeptide is an AAV rep62 protein.
- 59. The recombinant HSV of claim 54, wherein the rep polypeptide is an AAV rep40 protein.
- 60. The recombinant HSV of claim 54, wherein the rep gene is not within the AAV ITR cassette.
- 61. The recombinant HSV of claim 54, which is deficient for at least one essential HSV gene.
- 62. The recombinant HSV of claim 61, wherein the essential HSV gene is an immediate early, early or late HSV gene.
  - 63. The recombinant HSV of claim 61, wherein the essential HSV gene is ICP27.
- 64. The recombinant HSV of claim 54, wherein the promoter is conditionally active.
- 65. The recombinant HSV of claim 54, wherein the promoter is a tissue specific promoter.
- 66. The recombinant HSV of claim 54, wherein the promoter is an HSV promoter.
- 67. The recombinant HSV of claim 54, which is replication incompetent in cells other than packaging cells.
  - 68. A viral stock comprising the recombinant HSV of claim 54.
- 69. A composition comprising the recombinant HSV of claim 54 and a physiologically-acceptable carrier.
  - 70. The composition of claim 69, which further comprises an ITR cassette.

